Interferon Alpha (IFNA) - Pipeline Review, H2 2016

  • ID: 4035460
  • Report
  • 47 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • Neovacs SA
  • PsiOxus Therapeutics Ltd
  • ZIOPHARM Oncology Inc
  • MORE
Interferon Alpha (IFNA) - Pipeline Review, H2 2016

Summary

‘Interferon Alpha (IFNA) - Pipeline Review, H2 2016’, provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interferon Alpha (IFNA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA)
- The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • Neovacs SA
  • PsiOxus Therapeutics Ltd
  • ZIOPHARM Oncology Inc
  • MORE
Introduction

Interferon Alpha (IFNA) Overview

Therapeutics Development

Interferon Alpha (IFNA) - Products under Development by Stage of Development

Interferon Alpha (IFNA) - Products under Development by Therapy Area

Interferon Alpha (IFNA) - Products under Development by Indication

Interferon Alpha (IFNA) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interferon Alpha (IFNA) - Products under Development by Companies

Interferon Alpha (IFNA) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interferon Alpha (IFNA) - Companies Involved in Therapeutics Development

Argos Therapeutics Inc

Neovacs SA

PsiOxus Therapeutics Ltd

ZIOPHARM Oncology Inc

Interferon Alpha (IFNA) - Drug Profiles

AGS-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NG-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTS-IFN Alpha - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interferon Alpha (IFNA) - Dormant Projects

Interferon Alpha (IFNA) - Discontinued Products

Interferon Alpha (IFNA) - Featured News & Press Releases

Dec 07, 2016: Neovacs obtains FDA "Fast Track" designation for IFNa Kinoid in Lupus (SLE)

Nov 23, 2016: 3P Biopharmaceuticals signs production partnership with Neovacs

Nov 07, 2016: Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus

Oct 12, 2016: Neovacs signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris

Apr 28, 2016: Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States

Apr 14, 2016: Neovacs obtains South Korea health authority approval for IND application with IFNa kinoid in Lupus

Jan 06, 2016: Neovacs Secures €5 Million, from the Public Funding Program to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kinoïd

Sep 24, 2015: Neovacs initiates phase IIb trial of IFNa-Kinoid for the treatment of lupus

Sep 17, 2015: Stellar Biotechnologies' Partner Neovacs Reports Potent and Long-Lasting Biological Activity of IFN-Alpha-Kinoid Immunotherapy 4 Years After Patient Dosing in Lupus Phase I/IIa Trial

Sep 09, 2015: Neovacs confirms potent and long-lasting biological activity of IFNa-Kinoid 4 years after patient dosing in phase I/IIa trial

Sep 01, 2015: Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

May 13, 2015: Neovacs granted 1.8 million euros in research tax credit

Apr 01, 2015: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Argos Therapeutics Inc, H2 2016

Pipeline by Neovacs SA, H2 2016

Pipeline by PsiOxus Therapeutics Ltd, H2 2016

Pipeline by ZIOPHARM Oncology Inc, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Argos Therapeutics Inc
  • Neovacs SA
  • PsiOxus Therapeutics Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll